Geographic atrophy in patients with advanced dry age-related macular degeneration: Current challenges and future prospects

Ronald P. Danis*, Jeremy Arlin Lavine, Amitha Domalpally

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


Geographic atrophy (GA) of the retinal pigment epithelium (RPE) is a devastating complication of age-related macular degeneration (AMD). GA may be classified as drusen-related (drusen-associated GA) or neovascularization-related (neovascular-associated GA). Drusen-related GA remains a large public health concern due to the burden of blindness it produces, but pathophysiology of the condition is obscure and there are no proven treatment options. Genotyping, cell biology, and clinical imaging point to upregulation of parainflammatory pathways, oxidative stress, and choroidal sclerosis as contributors, among other factors. Onset and monitoring of progression is accomplished through clinical imaging instrumentation such as optical coherence tomography, photography, and autofluorescence, which are the tools most helpful in determining end points for clinical trials at present. A number of treatment approaches with diverse targets are in development at this time, some of which are in human clinical trials. Neovascular-associated GA is a consequence of RPE loss after development of neovascular AMD. The neovascular process leads to a plethora of cellular stresses such as ischemia, inflammation, and dramatic changes in cell environment that further taxes RPE cells already dysfunctional from drusen-associated changes. GA may therefore develop secondary to the neovascular process de novo or preexisting drusen-associated GA may continue to worsen with the development of neovascular AMD. Neovascular-associated GA is a prominent cause of continued vision loss in patients with otherwise successfully treated neovascular AMD. Clearly, treatment with vascular endothelial growth factor (VEGF) inhibitors early in the course of the neovascular disease is of great clinical benefit. However, there is a rationale and some suggestive evidence that anti-VEGF agents themselves could be toxic to RPE and enhance neovascular-associated GA. The increasing prevalence of legal blindness from this condition due to the aging of the general population lends urgency to the search for a therapy to ameliorate GA.

Original languageEnglish (US)
Pages (from-to)2159-2174
Number of pages16
JournalClinical Ophthalmology
StatePublished - Nov 20 2015


  • Age-related macular degeneration
  • Clinical trials
  • Fundus autofluorescence
  • Geographic atrophy
  • Optical coherence tomography

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Geographic atrophy in patients with advanced dry age-related macular degeneration: Current challenges and future prospects'. Together they form a unique fingerprint.

Cite this